All Oncology News

Suresh A. Ramalingam, MD, discusses the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting of non-small cell lung cancer.

Rana R. McKay, MD, discusses the promising findings from the CheckMate-214 and CABOSUN studies in renal cell carcinoma.

The FDA approved abemaciclib (Verzenio) for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy. The CDK4/6 inhibitor has also been approved as a monotherapy for patients with HR+/HER2- breast cancer with metastatic disease who have previously received endocrine therapy and chemotherapy.

Harry Erba, MD, PhD, reflects on the 4 approvals and their effect on the treatment of AML moving forward.

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

Thomas Hope, MD, discusses the novel technique PSMA-PET and how, if approved, it will significantly alter detection of biochemically recurrent prostate cancer.

The Japanese Ministry of Health, Labor and Welfare has approved avelumab (Bavencio) for use in patients with metastatic Merkel cell carcinoma, according to Merck KGaA.

Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field.

Toni K. Choueiri, MD, sheds light on the excitement surrounding the CABOSUN and CheckMate-214 trials, and why the future of the renal cell carcinoma field lies in novel combination regimens.

The FDA has accepted a supplemental new drug application for lenvatinib as a frontline systemic treatment for patients with advanced hepatocellular carcinoma.

Charles Ryan, MD, discusses the evolution of zoledronic acid and denosumab, and the future role of radium-223 as it begins to be studied in combination regimens in prostate cancer.

Sumanta Kumar Pal, MD, discusses the scope of exciting genitourinary cancer data presented at the 2017 ESMO Congress, with a sharp focus on the CABOSUN and CheckMate-214 trials.

Patients with advanced renal cell carcinoma with bone metastases had reductions in bone-turnover markers when treated with radium-223 dichloride and a VEGF inhibitor, although the incidence of symptomatic skeletal events remained high.

Half of patients with melanoma who progressed on anti-PD-1/PD-L1 therapy benefited from the combination of nivolumab and the LAG-3 inhibitor relatlimab.

Patients with metastatic renal cell carcinoma appeared to derive a substantial survival benefit with rocapuldencel-T, an immunotherapy made from dendritic cells.

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.

The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non-small cell lung cancer and previously-treated locally advanced or metastatic urothelial carcinoma.

The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib.

Guy Young, MD, discussed the use of anticoagulants in managing thromboembolic events in pediatric cancer.

The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy.

Treatment with the BCL-2 inhibitor venetoclax (Venclexta) led to negative minimal residual disease (MRD) status in 40% of evaluable patients with relapsed/refractory chronic lymphocytic leukemia.

Women with node-positive stage IIIC endometrial cancer assigned to adjuvant chemoradiation therapy had better survival than those assigned to chemotherapy or radiation therapy alone.

Dose-dense chemotherapy could be a superior option for adjuvant treatment of endometrial cancer compared with standard chemotherapy.

Giampero (John) A. Martignetti, MD, PhD, explains that more large-size clinical trials need to be conducted to answer some of the burgeoning questions in the fallopian tube and ovarian cancer landscape.

Rahul Aggarwal, MD, discussed the success of recent studies of androgen-deprivation therapy in prostate cancer, as well as its future utilization in various stages of disease.

Some patients with mantle cell lymphoma can delay treatment without experiencing negative outcomes, according to findings from a population-based study.

The European Commission has approved avelumab (Bavencio) for the treatment of patients with metastatic Merkel cell carcinoma.